Sharp begins validation phase of £9.5 million Clinical Services Centre of Excellence
![](/46/pdcnewsitem/07/44/53/Sharp%20Rhymney%20UK%202.png)
Investment will triple Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.
Sharp - part of UDG Healthcare - has begun the validation phase of Sharp UK, a £9.5 million Clinical Services Centre of Excellence in Rhymney, Wales.
Development of the state-of-the-art, multiple-phase pharmaceutical manufacturing, packaging and distribution facility began in 2017 and is now complete.
The first phase of the expansion has involved renovation of a 10,200 m2 GMP facility on the 11-acre site which will offer clinical trial supplies packaging, labelling, distribution, QP services as well as secure drug storage.
Frank Lis, president of Sharp Clinical Services, said: “Investing in new facilities and increasing our capacity enables Sharp to be even more responsive to customer requirements, while also meeting the growing demand for our services.”
Investment in the facility, which included £500,000 from the Welsh Government, enables the company to satisfy increased demand for Global clinical and commercial services. Once complete, it will triple Sharp’s clinical service capacity for the pharmaceutical, biotech and clinical research sectors.
“Sharp UK will allow us to offer a broader range of integrated services from a world-class clinical facility. As such we are developing our manufacturing and analytical capabilities and adding automated bottling, blistering and serialisation as well as Interactive Response Technology (IRT) services for clinical trial management.”
“This means we will be able to offer full-service support for larger global clinical studies from this new Clinical Services Centre of Excellence.”
The new facility will create 73 new jobs and safeguard a further 70 with support from the Welsh Government.
![SHARP](https://www.cphi-online.com/logo-comp248619.jpeg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance